NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $11.75 +0.47 (+4.17%) Closing price 04:00 PM EasternExtended Trading$11.78 +0.03 (+0.21%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ADMA Biologics Stock (NASDAQ:ADMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$11.34▼$11.7750-Day Range$8.61▼$11.2852-Week Range$7.21▼$20.46Volume2.74 million shsAverage Volume4.09 million shsMarket Capitalization$2.63 billionP/E Ratio16.79Dividend YieldN/APrice Target$18.67Consensus RatingModerate Buy Company Overview ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases. ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency. The company also markets Nabi-HB, a hepatitis B immune globulin used for post-exposure prophylaxis and in other settings where protection against hepatitis B infection is needed. Headquartered in Boca Raton, Florida, ADMA operates primarily in the United States and serves the specialty plasma-derived therapeutics market through healthcare providers, specialty pharmacies and other distribution channels. The company was founded in 2007 and has been led by Adam Grossman, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More ADMA Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreADMA MarketRank™: 4.119164302295 of 5 starsADMA Biologics scored higher than 82% of companies evaluated by MarketBeat, and ranked 82nd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingADMA Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialADMA Biologics has a consensus price target of $18.67, representing about 58.9% upside from its current price of $11.75.Amount of Analyst CoverageADMA Biologics has only been the subject of 2 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.97% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 8.97% in the coming year, from $0.78 to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 16.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.09.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 16.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 37.16.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.07% of the float of ADMA Biologics has been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 6.55.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 5.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.82 News SentimentADMA Biologics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ADMA Biologics this week, compared to 8 articles on an average week.Search Interest13 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.MarketBeat Follows4 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders3.90% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADMA Stock News HeadlinesADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026October 28 at 7:00 AM | globenewswire.comADMA Biologics (NASDAQ:ADMA) Share Price Breaks Above Two Hundred Day Moving Average - Here's WhyOctober 28 at 3:21 AM | americanbankingnews.comThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Starlink dish and AI satellite Elon launches. When Nvidia tried to buy the company, Elon reportedly fought the deal. Now his filing for 1,000,000 satellites could expand its revenue stream sharply. Dylan believes the stock could see significant movement starting December 8th.October 29 at 1:00 AM | Behind the Markets (Ad)Could ADMA Biologics' New IVIG Data Be A Catalyst For Investor Interest?October 15, 2026 | rttnews.comHow Investors May Respond To ADMA Biologics (ADMA) Peer‑Reviewed Validation Of IVIG Safety And PurityOctober 15, 2026 | finance.yahoo.comADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing ProcessOctober 15, 2026 | globenewswire.comADMA Biologics (ADMA), Why Is It Back In The Spotlight?September 27, 2026 | finance.yahoo.comBerger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)September 8, 2026 | prnewswire.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $18.24 on January 1st, 2026. Since then, ADMA shares have decreased by 35.6% and is now trading at $11.7450. How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) issued its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by $0.00. ADMA Biologics's revenue for the quarter was up 2.0% compared to the same quarter last year. Read the conference call transcript. When did ADMA Biologics IPO? ADMA Biologics (ADMA) raised $30 million in an initial public offering (IPO) on the week of November 10th 2014. The company issued 3,352,941 shares at $8.50-$9.50 per share. Who are ADMA Biologics' major shareholders? Top institutional investors of ADMA Biologics include State of Alaska Department of Revenue (0.04%), Motley Fool Asset Management LLC, VIRGINIA RETIREMENT SYSTEMS ET Al (0.04%) and Profund Advisors LLC (0.03%). Insiders that own company stock include Adam S Grossman, Steve Elms, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade and Lawrence P Guiheen. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Ford Motor (F), Micron Technology (MU) and Viking Therapeutics (VKTX). Company Calendar Last Earnings8/05/2026Today10/29/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 9 days, ADMA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ADMA CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees647Year Founded2004Price Target and Rating Average Price Target for ADMA Biologics$18.67 High Price Target$21.00 Low Price Target$17.00 Potential Upside/Downside+58.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio16.79 Forward P/E Ratio15.06 P/E GrowthN/ANet Income$146.93 million Net Margins32.98% Pretax Margin42.26% Return on Equity40.17% Return on Assets26.97% Debt Debt-to-Equity Ratio0.49 Current Ratio6.97 Quick Ratio3.81 Sales & Book Value Annual Sales$510.17 million Price / Sales5.16 Cash Flow$0.72 per share Price / Cash Flow16.33 Book Value$2.01 per share Price / Book5.85Miscellaneous Outstanding Shares223,990,000Free Float215,250,000Market Cap$2.63 billion OptionableOptionable Beta0.70 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ADMA) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
